37% of trials started over the last 10 years are still recruiting participants
- Out of 497 trials recorded by Beacon, 334 trials registered to start between 2010 -2020
- Of these trials, 85% are in phase 1-2, and 32% are already reporting efficacy data
53% of virotherapy assets are preclinical
The field began to gain more traction after the FDA & EMA approval of Talimogene Laherparepvec for the treatment of advanced melanoma.
2 Discontinued (Officially)
The struggle to enrol patients remains; however, with more trials at play, more data will become available to the community.
The race in virotherapy development has non-profit organizations and higher education developers investing as much time as Large Pharma. Who will make the next approval?
With a significant number of virotherapy options being studied both in the clinic and the lab, could combining virotherapies with Checkpoints make them stronger contenders?
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements